BIOCATALYSIS - Biocatalysis Without Barriers for Efficient Small Molecule Process Development
Masha Kononov and Reuben Carr examine both the promise and the practical constraints of biocatalysis in modern drug substance development, as well as the role of contract research, development and manufacturing organizations (CRD-MOs) in meeting the evolving demands of modern small molecule synthesis.
SPECIAL FEATURE - PFS & Parenteral Manufacturing: Rapid Growth of Injectables Places Unprecedented Demands on Parenteral Manufacturing
Contributor Cindy H. Dubin highlights many of these CDMOs as well as innovations in the PFS sector.
FORMULATION FORUM - Supercritical Carbon Dioxide (scCO2) for Improving Solubility & Oral Bioavailability of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, discuss as more new chemical entities coming out of discovery are poorly soluble (BCS Class II and IV), the scCO2 is taking an aim to find the desired solutions to help improve the bottleneck in the industry.
TKIS - Next-Generation BCR-ABL TKIs for CML: The Allosteric Era
Emil Kuriakose, MD, explores the current CML treatment landscape, ongoing clinical challenges, and the potential of next-generation TKIs currently in development, offering hope for the growing CML community.
SELF ADMINISTRATION - Smarter, Kinder, Simpler: EcoSafe Sets a New Standard for Sustainable Self-Administration
Mark Glass takes a novel approach to serve a patient group, with the ambitious aims of increasing the inclusivity of its existing 1mL safety syringe, simplifying procurement, reducing cost, and reducing carbon footprint.
EXCIPIENTS - Strategic Excipient Sourcing: Navigating Supply Chain Resilience, Quality & Sustainability by Design
Nick DiFranco, MEM, explores the critical considerations drug developers must evaluate when selecting an excipient partner today.
EXECUTIVE INTERVIEW - Resilience: From Complexity to Clarity - Sharpening Focus for Long-Term Performance in a More Demanding CDMO Era
Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.
IPSC-NK THERAPIES - Advancing Allogeneic Platforms: The Future of Scalable iPSC-NK Therapies
Stefan Braam, PhD, explores how developers across the industry are tackling these challenges through process optimization, automation, and gene editing innovations. These efforts aim to deliver robust, cost-effective allogeneic platforms that meet the demands of modern healthcare.
EXECUTIVE INTERVIEW - Vetter Pharma: Why Fill-Finish Matters More Than Ever – & the Trends Behind It
Carsten Press, one of Vetter’s Managing Directors, discusses the key trends shaping CDMO innovation in today’s dynamic market – and how the family-owned company is integrating these trends into its forward-looking strategy to support consistent quality and seamless drug delivery.
CAR-T CELLS - The Growing Benefits of CAR-T Cells in Cancer Research & Beyond
Michael Kapinsky, PhD, says successful management or even curing a growing range of severe diseases, often lacking sufficient treatment options, seems to be in reach using CAR-engineered immune cells.
NASAL DELIVERY - Blazing a Trail to Patient-Friendly CNS Therapies: Exploring The Promise, Progress & Challenges of Nose-to-Brain Drug Delivery
Justin Lygrisse explores the rationale behind nose-to-brain delivery and the early clinical and preclinical efforts now underway to assess its potential.
SPECIAL FEATURE - Bioavailability & Solubility: Experimental Techniques Combined With Computational Decision-Making Rapidly ID the Most Viable Enhancement Pathway
Contributor Cindy H. Dubin highlights other ways formulators are relying on automation, such as Artificial Intelligence and Machine Learning, and how these tools are being combined with experimental confirmation to identify the most promising development strategies.
ARTIFICIAL INTELLIGENCE - The AI-Driven Path to Precision Therapeutics
Rotem Gura-Sadovsky, PhD, and Maayan Eilon-Ashkenazy, PhD, explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.
BIOAVAILABILITY & SOLUBILITY - Formulation Strategies for Tackling Poor Oral Bioavailability
Richard Johnson, PhD, says better characterization of NCEs in the early stages of development and identifying solubility issues early offers the opportunity to address poor bioavailability using formulation techniques that deliver enhanced drug exposure – reducing risk, conserving resources, and increasing the chances of clinical success.
CML ADVANCES - To Improve Upon a Miracle Drug: Overcoming Drug Resistance & Intolerance in CML
Ben Hohl, says while imatinib and other TKIs have undoubtedly positively impacted the lives of many people living with CML, thousands of patients are still looking for drugs that provide better efficacy, tolerability, and convenience.
Expert Insights Videos
Go beyond the written word with our new podcast series, featuring in-depth conversations with industry leaders shaping the future of drug development and delivery. Each episode explores real-world challenges, emerging technologies, and the insights driving innovation across the pharmaceutical landscape.
Enhancing Drug Bioavailability: Solubility Techniques and Innovations
Improving the bioavailability of poorly soluble drugs continues to be a critical focus in pharmaceutical development. Many active pharmaceutical ingredients (APIs), particularly those classified under…
Better Bioavailability Faster Timelines with Ascendia Pharmaceutical Solutions
In the rapidly evolving world of pharmaceuticals, understanding the intricacies of drug development is essential for anyone interested in healthcare innovation. In this episode of…
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products
In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.
On-Demand Presentation: Analytical Strategy & Challenges for ADC
Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.
America’s Next Healthcare Crisis Is Already Here - And We’re Not Ready
Bryn L. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy. Dubin has federal and state legislative and policy analysis experience.
Executive Interview: Advancing Regenerative Medicine for Chronic Disease
Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.
eBook: Understanding the Foundation of LNP Formulation Success
Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
Have expert content to share? Contact us
WHITEPAPERS & WEBINARS
WHITEPAPER - From Service Provider to Strategic Partner
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability.
WHITE PAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development
This article explores how AI-driven predictive insights reduce uncertainty in early oral drug development, enabling smarter decisions on solubility, dosing, stability, and scale-up while preserving API, accelerating timelines, and de-risking clinical success .
WHITE PAPER - Small Molecules: Choosing the Right Development Path
This white paper outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
WHITE PAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford, review how for many high-potency APIs, micronization is not a downstream convenience but a critical performance step. Particle size distribution directly influences dissolution behavior, bioavailability, blend uniformity, and dose accuracy, particularly when therapeutic doses are measured in micrograms.
WHITE PAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations
This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as the Mantoux technique with modern innovations such as the Terumo Immucise™ Intradermal Injection System.
WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
There are three key factors that need to be controlled when designing a drug product for solubility enhancement: the polymeric carrier; the manufacturing process; and the match to the desired API. By controlling these three factors bioavailability, drug release profile and manufacturability of your final drug product can be controlled.
WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine
Enabling technologies such as Nanotechnology, Amorphous Solid Dispersions, Self-emulsifying/nanoemulsifying drug delivery systems (SEDDS/SNEDDS) or Lipid Nano Particles (LNPs) for oral delivery are key elements for the development of complex and difficult to develop small molecules.
ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
MARKET NEWS & TRENDS
Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program
Hongene Biotech Corporation recently announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end…
Bracco Launches BubbleGen Early Access Program for Microbubble-Based Cell Selection & Activation at ISCT
Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program to enable cell therapy developers to evaluate the…
Single-Cell Multiomics Enables High-Resolution Vector Copy Number Profiling in CAR-T Therapie
Mission Bio, the leader in single-cell multiomics, published research in Molecular Therapy Advances showing that its Tapestri® platform can profile vector copy number (VCN), surface…
Ecolab Life Sciences Opens Bioprocessing Applications Lab in Korea to Support Downstream Process Development Across Asia
Ecolab Life Sciences is expanding the bioprocessing business with the launch of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, giving biopharmaceutical manufacturers across…
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
Achieve Life Sciences, Inc.recently announced significant operational progress including the transfer of cytisinicline manufacturing to U.S.-based Adare Pharma Solutions (Adare). Achieve has now completed the…
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish & Drug-Device Delivery Combination Capabilities
PCI Pharma Services – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a…
Cellares & Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. (Nasdaq:…
Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced the first subject has been dosed in…
Bio-Rad Launches PTC Harmony 96 & PTC Harmony Deepwell Thermal Cyclers
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the PTC…
PTC Therapeutics to Report Results From PIVOT-HD Long-Term Extension Study
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim…
Evonik & Higuchi Strengthen Oral Drug Delivery Innovation in Japan With New Joint Laboratory
Evonik and Higuchi Inc., a leading Japanese trading company in the pharmaceutical sector, are opening a joint laboratory located in Yokohama, Japan. The “Open Pharma…
BD & Suttons Creek Partner to Help Pharma a& Biotech Companies Deliver Combination Products to Market With Confidence
Becton, Dickinson and Company (BD) (NYSE:BDX), one of the largest global medical technology companies in the world, and Suttons Creek, a BlueRidge Life Sciences company,…
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced positive topline results…
Evonik Strengthens Biotechnology Capabilities for Drug Substance Manufacturing With New Investment in Slovakia
Evonik is investing around EUR 80 million to expand its biotechnology capabilities at its Fermas site in Slovenská Ľupča, Slovakia. The investment will add state-of-the-art…
Alcami to Acquire Contract Packaging Organization Tjoapack
Alcami Corporation recently announced it has entered into a definitive agreement to acquire Tjoapack, a leading global contract packaging organization with facilities in the United…
MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, recently announced the launch of the…
Crown Bioscience & Turbine Partner to Connect AI-Driven Prediction With Organoid Validation in Translational Oncology
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology…
Gerresheimer & Milliken Partner to Advance Performance & Protection With LeneX UltraGuard Technology
Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, recently announced a partnership with Milliken &…
Piramal Pharma Solutions & Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development & Manufacturing
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration. Under this collaboration, Piramal will refer applicable customers seeking ADC manufacturing technology to…
Nemera Announces Construction of a New Production Hall
Nemera, a global leader in drug delivery devices, recently announced the groundbreaking ceremony for a new production hall at its La Verpillière site (Isère, France).…
